REGENXBIO Inc. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax
REGENXBIO Inc. (RGNX) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax of $11.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax · last filed 2026-08-06
- REGENXBIO Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2026-06-30 was $11.00K, a 8.33% decline year-over-year.
- REGENXBIO Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2025-06-30 was $12.00K.
- REGENXBIO Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2023-12-31 was $2.98M, a 4.52% increase year-over-year.
- REGENXBIO Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2023-09-30 was $2.69M.
- REGENXBIO Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2024 was $3.69M, a 66.39% decline from fiscal 2023.
- REGENXBIO Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2023 was $10.97M.
- REGENXBIO Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2022 was -$12.90M.
- REGENXBIO Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2021 was -$2.20M.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 3 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 6 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 9 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 12 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $11.00K 10-Q · filed 2026-08-06 | -$172.00K 10-Q · filed 2026-08-06 | ||||||
| 2025-06-30 | $12.00K 10-Q · filed 2026-08-06 | -$9.00K 10-Q · filed 2026-08-06 | ||||||
| 2024-12-31 | $3.69M 10-K · filed 2025-03-13 | |||||||
| 2023-12-31 | $2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $5.67M derived: sum of 2 quarters · filed 2025-03-13 | $7.19M derived: sum of 3 quarters · filed 2025-03-13 | $10.97M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | $2.69M 10-Q · filed 2023-11-08 | $4.21M derived: sum of 2 quarters · filed 2023-11-08 | $7.99M 10-Q · filed 2023-11-08 | $10.84M derived: sum of 4 quarters · filed 2025-03-13 | ||||
| 2023-06-30 | $1.52M 10-Q · filed 2023-08-02 | $5.30M 10-Q · filed 2023-08-02 | $8.16M derived: sum of 3 quarters · filed 2025-03-13 | $4.67M derived: sum of 4 quarters · filed 2025-03-13 | ||||
| 2023-03-31 | $3.78M 10-Q · filed 2023-05-03 | $6.63M derived: sum of 2 quarters · filed 2025-03-13 | $3.14M derived: sum of 3 quarters · filed 2025-03-13 | $256.00K derived: sum of 4 quarters · filed 2025-03-13 | ||||
| 2022-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$638.00K derived: sum of 2 quarters · filed 2025-03-13 | -$3.52M derived: sum of 3 quarters · filed 2025-03-13 | -$12.90M 10-K · filed 2025-03-13 | ||||
| 2022-09-30 | -$3.49M 10-Q · filed 2023-11-08 | -$6.38M derived: sum of 2 quarters · filed 2023-11-08 | -$15.76M 10-Q · filed 2023-11-08 | -$17.04M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | -$2.88M 10-Q · filed 2023-08-02 | -$12.27M 10-Q · filed 2023-08-02 | -$13.55M derived: sum of 3 quarters · filed 2024-02-27 | -$13.58M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | -$9.38M 10-Q · filed 2023-05-03 | -$10.66M derived: sum of 2 quarters · filed 2024-02-27 | -$10.70M derived: sum of 3 quarters · filed 2024-02-27 | -$10.58M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | -$1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$1.31M derived: sum of 2 quarters · filed 2024-02-27 | -$1.20M derived: sum of 3 quarters · filed 2024-02-27 | -$2.20M 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | -$30.00K 10-Q · filed 2022-11-03 | $83.00K derived: sum of 2 quarters · filed 2022-11-03 | -$918.00K 10-Q · filed 2022-11-03 | -$1.45M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | $113.00K 10-Q · filed 2022-08-03 | -$888.00K 10-Q · filed 2022-08-03 | -$1.42M derived: sum of 3 quarters · filed 2023-02-28 | -$1.88M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | -$1.00M 10-Q · filed 2022-05-04 | -$1.53M derived: sum of 2 quarters · filed 2023-02-28 | -$1.99M derived: sum of 3 quarters · filed 2023-02-28 | -$672.00K derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | -$534.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$991.00K derived: sum of 2 quarters · filed 2023-02-28 | $329.00K derived: sum of 3 quarters · filed 2023-02-28 | -$426.00K 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | -$457.00K 10-Q · filed 2021-11-02 | -$500.00K 10-Q · filed 2020-11-04 | $863.00K derived: sum of 2 quarters · filed 2021-11-02 | $108.00K 10-Q · filed 2021-11-02 | $100.00K 10-Q · filed 2020-11-04 | -$200.00K derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $1.32M 10-Q · filed 2021-08-09 | -$1.30M 10-Q · filed 2020-08-06 | $565.00K 10-Q · filed 2021-08-09 | $600.00K 10-Q · filed 2020-08-06 | $257.00K derived: sum of 3 quarters · filed 2022-03-01 | $157.00K derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | -$755.00K 10-Q · filed 2021-05-05 | -$800.00K 10-Q · filed 2020-05-07 | -$1.06M derived: sum of 2 quarters · filed 2022-03-01 | -$1.16M derived: sum of 3 quarters · filed 2022-03-01 | -$363.00K derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | -$308.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$408.00K derived: sum of 2 quarters · filed 2022-03-01 | $392.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.39M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | -$100.00K 10-Q · filed 2020-11-04 | $700.00K derived: sum of 2 quarters · filed 2020-11-04 | $1.70M 10-Q · filed 2020-11-04 | $1.46M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $800.00K 10-Q · filed 2020-08-06 | $1.80M 10-Q · filed 2020-08-06 | $1.56M derived: sum of 3 quarters · filed 2021-03-01 | $1.66M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $1.00M 10-Q · filed 2020-05-07 | $756.00K derived: sum of 2 quarters · filed 2021-03-01 | $856.00K derived: sum of 3 quarters · filed 2021-03-01 | $956.00K derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | -$244.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$144.00K derived: sum of 2 quarters · filed 2021-03-01 | -$44.00K derived: sum of 3 quarters · filed 2021-03-01 | -$44.00K 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $100.00K 10-Q · filed 2019-11-05 | -$100.00K 10-Q · filed 2018-11-07 | $200.00K derived: sum of 2 quarters · filed 2019-11-05 | $200.00K 10-Q · filed 2019-11-05 | -$200.00K 10-Q · filed 2018-11-07 | |||
| 2018-06-30 | $100.00K 10-Q · filed 2019-08-07 | -$100.00K 10-Q · filed 2019-08-07 | ||||||
| 2018-03-31 | -$200.00K 10-Q · filed 2019-05-07 | |||||||
| 2017-12-31 | -$200.00K 10-K · filed 2018-03-06 | |||||||
| 2017-09-30 | $100.00K 10-Q · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | -$100.00K derived: sum of 3 quarters · filed 2018-11-07 | -$600.00K derived: sum of 4 quarters · filed 2018-11-07 | ||||
| 2017-06-30 | -$100.00K 10-Q · filed 2018-08-08 | -$100.00K 10-Q · filed 2018-08-08 | -$700.00K derived: sum of 3 quarters · filed 2018-08-08 | -$400.00K derived: sum of 4 quarters · filed 2018-08-08 | ||||
| 2017-03-31 | -$100.00K 10-Q · filed 2018-05-08 | -$600.00K derived: sum of 2 quarters · filed 2018-05-08 | -$300.00K derived: sum of 3 quarters · filed 2018-05-08 | -$100.00K derived: sum of 4 quarters · filed 2018-05-08 | ||||
| 2016-12-31 | -$500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | -$200.00K derived: sum of 2 quarters · filed 2018-03-06 | $0.00 derived: sum of 3 quarters · filed 2018-03-06 | $1.10M 10-K · filed 2018-03-06 | ||||
| 2016-09-30 | $300.00K 10-Q · filed 2017-11-08 | $500.00K derived: sum of 2 quarters · filed 2017-11-08 | $1.60M 10-Q · filed 2017-11-08 | |||||
| 2016-06-30 | $200.00K 10-Q · filed 2017-08-08 | $1.20M 10-Q · filed 2017-08-08 | ||||||
| 2015-12-31 | -$700.00K 10-K · filed 2018-03-06 | -$700.00 10-K · filed 2017-03-07 | ||||||
| 2014-12-31 | $0.00 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |